23andMe Holding Co. at Citi Healthcare & Medtech Conference Transcript

Mar 01, 2023 / 02:30PM GMT
Daniel R. Grosslight - Citigroup Inc., Research Division - Research Analyst

All right. We shall begin again. So Daniel Grosslight, Healthcare Technology Analyst here at Citi, joined by Joe Selsavage, the CFO of 23andMe. Thank you all for joining us today. You know 23andMe is a bit of an (inaudible), if you don't mind me saying that, in that there's a lot of different types of companies in one. So I guess just see the sense of the room here. How many of you folks are focused more on biotech, life sciences. A couple health tech diagnostics. So it's a fair mix, which I think is -- brings a lot of opportunity but also perhaps one great home for you, which tends to be an issue, some of that.

Questions and Answers:

Daniel R. Grosslight - Citigroup Inc., Research Division - Research Analyst

So I guess if we just start off to begin with on the consumer side, you had a good quarter this past quarter in terms of kit demand. That's where people, I think most know you from reflects a little less discounting this quarter than perhaps in previous quarters. So can you
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot